7 results

  • bkemv

    (eculizumab-aeeb)
    Amgen Inc
    BKEMV is indicated for treating paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis, atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy, and generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AchR) antibody positive.

  • empaveli

    (Pegcetacoplan)
    Apellis Pharmaceuticals, Inc.
    EMPAVELI® is indicated for treating adult patients with paroxysmal nocturnal hemoglobinuria (PNH).

  • izervay

    (avacincaptad pegol)
    Astellas Pharma US, Inc.
    IZERVAY™ is indicated for the treatment of geographic atrophy (GA) associated with age-related macular degeneration (AMD).

  • soliris

    (ECULIZUMAB)
    Alexion Pharmaceuticals Inc.
    SOLIRIS is indicated for treating paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG) in patients six years or older who are anti-AChR antibody positive, and neuromyelitis optica spectrum disorder (NMOSD) in anti-AQP4 antibody positive adults.

  • syfovre

    (Pegcetacoplan)
    Apellis Pharmaceuticals, Inc.
    SYFOVRE is indicated for the treatment of geographic atrophy (GA) due to age-related macular degeneration (AMD).

  • ultomiris

    (ravulizumab)
    Alexion Pharmaceuticals Inc.
    ULTOMIRIS is indicated for treating paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS) in patients aged one month and older, generalized myasthenia gravis (gMG) in AChR antibody-positive adults, and neuromyelitis optica spectrum disorder (NMOSD) in AQP4 antibody-positive adults.

  • veopoz

    (Pozelimab)
    Regeneron Pharmaceuticals, Inc.
    VEOPOZ is indicated for the treatment of protein-losing enteropathy (PLE), specifically CD55-deficient PLE, in adult and pediatric patients aged 1 year and older.